178 related articles for article (PubMed ID: 30465157)
1. Impact of preexisting mental illness on breast cancer endocrine therapy adherence.
Haskins CB; McDowell BD; Carnahan RM; Fiedorowicz JG; Wallace RB; Smith BJ; Chrischilles EA
Breast Cancer Res Treat; 2019 Feb; 174(1):197-208. PubMed ID: 30465157
[TBL] [Abstract][Full Text] [Related]
2. Effects of Previous Medication Regimen Factors and Bipolar and Psychotic Disorders on Breast Cancer Endocrine Therapy Adherence.
Haskins CB; Neuner JM; McDowell BD; Carnahan RM; Fiedorowicz JG; Wallace RB; Smith BJ; Chrischilles EA
Clin Breast Cancer; 2020 Jun; 20(3):e261-e280. PubMed ID: 32139273
[TBL] [Abstract][Full Text] [Related]
3. Impact of patient race and geographical factors on initiation and adherence to adjuvant endocrine therapy in medicare breast cancer survivors.
Camacho FT; Tan X; Alcalá HE; Shah S; Anderson RT; Balkrishnan R
Medicine (Baltimore); 2017 Jun; 96(24):e7147. PubMed ID: 28614244
[TBL] [Abstract][Full Text] [Related]
4. Endocrine adherence in male versus female breast cancer: a seer-medicare review.
Ali A; Xie Z; Stanko L; De Leo E; Hong YR; Bian J; Daily KC
Breast Cancer Res Treat; 2022 Apr; 192(3):491-499. PubMed ID: 35142938
[TBL] [Abstract][Full Text] [Related]
5. Association Between Out-Of-Pocket Costs, Race/Ethnicity, and Adjuvant Endocrine Therapy Adherence Among Medicare Patients With Breast Cancer.
Farias AJ; Du XL
J Clin Oncol; 2017 Jan; 35(1):86-95. PubMed ID: 28034069
[TBL] [Abstract][Full Text] [Related]
6. Breast cancer endocrine therapy adherence in health professional shortage areas: Unique effects on patients with mental illness.
Haskins CB; McDowell BD; Carnahan RM; Fiedorowicz JG; Wallace RB; Smith BJ; Chrischilles EA
J Psychosom Res; 2021 Jan; 140():110294. PubMed ID: 33232903
[TBL] [Abstract][Full Text] [Related]
7. Opioid use among female breast cancer patients using different adjuvant endocrine therapy regimens.
Tan X; Camacho TF; LeBaron VT; Blackhall LJ; Balkrishnan R
Breast Cancer Res Treat; 2017 Sep; 165(2):455-465. PubMed ID: 28639031
[TBL] [Abstract][Full Text] [Related]
8. Racial Differences in Adjuvant Endocrine Therapy Use and Discontinuation in Association with Mortality among Medicare Breast Cancer Patients by Receptor Status.
Farias AJ; Du XL
Cancer Epidemiol Biomarkers Prev; 2017 Aug; 26(8):1266-1275. PubMed ID: 28515111
[No Abstract] [Full Text] [Related]
9. Patterns of endocrine therapy in a national cohort of early stage HER2-positive breast cancer patients.
Tervonen HE; Daniels B; Tang M; Preen DB; Pearson SA
Pharmacoepidemiol Drug Saf; 2019 Jun; 28(6):812-820. PubMed ID: 30861596
[TBL] [Abstract][Full Text] [Related]
10. Mental Health Comorbidities and Elevated Risk of Opioid Use in Elderly Breast Cancer Survivors Using Adjuvant Endocrine Treatments.
Desai R; Camacho F; Tan X; LeBaron V; Blackhall L; Balkrishnan R
J Oncol Pract; 2019 Sep; 15(9):e777-e786. PubMed ID: 31322988
[TBL] [Abstract][Full Text] [Related]
11. Outcomes of primary endocrine therapy in elderly women with stage I-III breast cancer: a SEER database analysis.
Yuan C; Xie Z; Bian J; Huo J; Daily K
Breast Cancer Res Treat; 2020 Apr; 180(3):819-827. PubMed ID: 32172303
[TBL] [Abstract][Full Text] [Related]
12. Predicting adjuvant endocrine therapy initiation and adherence among older women with early-stage breast cancer.
Meneveau MO; Keim-Malpass J; Camacho TF; Anderson RT; Showalter SL
Breast Cancer Res Treat; 2020 Dec; 184(3):805-816. PubMed ID: 32920742
[TBL] [Abstract][Full Text] [Related]
13. Adherence status to Adjuvant Endocrine Therapy in Chinese Women with Early Breast Cancer and its influencing factors: A cross-sectional survey.
Xu H; Jin F; Zhang XJ; Wang DQ; Yu SF; Wang AP
Cancer Med; 2020 Jun; 9(11):3703-3713. PubMed ID: 32237070
[TBL] [Abstract][Full Text] [Related]
14. Are breast cancer patients with suboptimal adherence to cardiovascular treatment more likely to discontinue adjuvant endocrine therapy? Competing risk survival analysis in a nationwide cohort of postmenopausal women.
Artignan J; Capmas P; Panjo H; Constantinou P; Pelletier-Fleury N
BMC Med; 2023 Nov; 21(1):463. PubMed ID: 38001491
[TBL] [Abstract][Full Text] [Related]
15. Adherence trajectories of adjuvant endocrine therapy in the five years after its initiation among women with non-metastatic breast cancer: a cohort study using administrative databases.
Lambert-Côté L; Bouhnik AD; Bendiane MK; Bérenger C; Mondor M; Huiart L; Lauzier S
Breast Cancer Res Treat; 2020 Apr; 180(3):777-790. PubMed ID: 32086655
[TBL] [Abstract][Full Text] [Related]
16. Ethnic differences in initiation and timing of adjuvant endocrine therapy among older women with hormone receptor-positive breast cancer enrolled in Medicare Part D.
Farias AJ; Du XL
Med Oncol; 2016 Feb; 33(2):19. PubMed ID: 26786154
[TBL] [Abstract][Full Text] [Related]
17. Geographic disparities in adherence to adjuvant endocrine therapy in Appalachian women with breast cancer.
Tan X; Camacho F; Marshall VD; Donohoe J; Anderson RT; Balkrishnan R
Res Social Adm Pharm; 2017; 13(4):796-810. PubMed ID: 27641308
[TBL] [Abstract][Full Text] [Related]
18. Evaluating the Long-Term Impact of a Cooperative Group Trial on Radiation Use and Adjuvant Endocrine Therapy Adherence Among Older Women.
Keim-Malpass J; Anderson RT; Balkrishnan R; Desai RP; Showalter SL
Ann Surg Oncol; 2020 Sep; 27(9):3458-3465. PubMed ID: 32270421
[TBL] [Abstract][Full Text] [Related]
19. Five-Year Adjuvant Endocrine Therapy Adherence Trajectories Among Women With Breast Cancer: A Nationwide French Study Using Administrative Data.
Lailler G; Memoli V; Le Bihan Benjamin C; Ben Diane MK; Lauzier S; Mancini J; Bousquet PJ; Bouhnik AD
Clin Breast Cancer; 2021 Aug; 21(4):e415-e426. PubMed ID: 33745868
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
